Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Stock (London, United Kingdom), A. De Lauretis (London, United Kingdom), D. Visca (London, United Kingdom), C. Daccord (London, United Kingdom), M. Kokosi (London, United Kingdom), V. Alfieri (London, United Kingdom), V. Kouranos (London, United Kingdom), G. Margaritopoulos (London, United Kingdom), P. George (London, United Kingdom), P. Molyneaux (London, United Kingdom), F. Chua (London, United Kingdom), T. Maher (London, United Kingdom), D. Abraham (London, United Kingdom), C. Denton (London, United Kingdom), V. Ong (London, United Kingdom), A. Wells (London, United Kingdom), E. Renzoni (London, United Kingdom). Verification of genetic associations with Scleroderma associated Interstitial Lung Disease. 5197

Member's Comments

No comment yet.

Related content which might interest you: Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): clinical heterogeneity and outcome Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 A Comparison of Pulmonary Rehabilitation Outcomes in Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used Source: International Congress 2017 – Rare diseases Year: 2017 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Predictive Findings of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019 The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Anti-synthetase syndrome associated Interstitial Lung Disease (ASS-ILD): Clinical, serological and radiological heterogeneity Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Unclassifiable Interstitial Lung Disease (ILD). Why? Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Associated Factors with the Approval of Pulmonary Rehabilitation for Inpatients with Interstitial Lung Disease: Two-center Retrospective Study Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Association of Metabolic Syndrome with the severity of Chronic Obstructive Pulmonary Disease Source: Virtual Congress 2020 – Clinical data and COPD management Year: 2020 Tuberculosis associated Obstructive Lung disease- A Pilot Study Source: International Congress 2018 – Airway disease: recent discoveries Year: 2018 Study to Evaluate Satisfaction with the Inhalation Device Used by Patients with Asthma or Chronic Obstructive Pulmonary Disease and the Association with Adherence and Disease Control Source: Virtual Congress 2020 – Novel insights into nursing interventions for managing patients with asthma and COPD Year: 2020 Pleural effusion in Niemann Pick Disease - associated Interstitial Lung Disease Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020 Gender perspective in Interstitial Lung Diseases (ILD) Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019